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Background
A major healthcare goal of the Scottish 
Government is to reduce alcohol-related harm, in 
all its many manifestations. However, much of the 
cost, morbidity and mortality of alcohol-related 
disease is driven by alcohol-related liver disease. 
SHAAP has convened a multi-disciplinary group 
of healthcare specialists to devise Good Practice 
Guidance, aimed at improving and standardising 
the level of care delivered for individuals at risk 
of and patients with alcohol-related liver disease 
nationwide. 
Liver disease is the fifth largest cause of death in the UK 
with the average age of death being 59 years in contrast to 
cardiovascular and respiratory disease, where the average 
age of death is nearly 80 years, making liver disease 
the third main cause of premature death in the UK. In 
Scotland this has equated to a rise in the death rates from 
chronic liver disease with 821 deaths in 2014, more than 
double that reported thirty years earlier and double what 
is recorded in England. Additionally, mortality rates vary 
across the country ranging from 9.1 per 105 population 
in Dumfries and Galloway to 21.5 per 105 population1 in 
Greater Glasgow and Clyde. These rates are also linked 
to social deprivation2 with those living in the most deprived 
areas having an eleven-fold increase in risk of death from 
liver disease in comparison to an individual in the least 
deprived areas. 
This is compounded by the five-fold increase in cirrhosis 
development in 35–55 year-olds over the past decade, 
which increases the risk of early death. Seventy per cent 
of UK hospital admissions for cirrhosis have alcohol as a 
major contributing factor. In the UK the past two decades 
have demonstrated a significant increase in the prevalence 
of chronic liver disease. The majority of this is due to 
alcohol-related liver disease as well as Hepatitis C and 
obesity-related liver disease. 
In view of the fact that 70% of liver cirrhosis is a 
consequence of alcohol, it is worthwhile highlighting that 
easy access to alcohol in terms of number of premises, 
days and hours of sales and availability in terms of area 
(m2) of shelf space devoted to alcohol all contribute to 
higher alcohol consumption. There should be a stronger 
pressure on licensing boards in areas where there 
is documented evidence of alcohol-related morbidity 
and mortality to restrict the growth of alcohol retailers. 
1  www.scotpho.org.uk/health-wellbeing-and-disease/chronic-liver-disease/
data/mortality
2  Bellis MA, Hughes K, Nicholls J, Sheron N and Jones L (2016) The alcohol harm 
paradox: using a national survey to explore how alcohol may disproportionately 
impact health in deprived individuals, BMC Public Health 16:111–121
Newsagents, takeaways, libraries, cinemas, theatres and 
cafes and sport clubs all now commonly apply for licences 
to sell alcohol. In addition, the overt display of alcohol 
consumption in our high streets and shopping centres due 
to the growth of pavement cafés and external drinking 
areas makes it very difficult to avoid exposure to areas 
where alcohol is consumed. As a society we are becoming 
de-sensitised to the ubiquitous presence of alcohol in our 
shopping and leisure activities.
A survey of Liver Services in Scotland published in 20133 
has demonstrated considerable variation between Scottish 
hospitals in the services available for patients with alcohol-
related liver disease. Many people who access health 
services are not routinely screened for alcohol problems 
and many who attend alcohol services are not being 
screened specifically for liver damage. The treatment and 
care delivered to individuals admitted to general hospitals 
with alcohol-related liver disease is variable, including not 
receiving appropriate follow-up to ensure their longer-term 
health. Equally, opportunities are missed to intervene when 
patients with alcohol-related liver failure have contact with 
hospital services for other reasons, whether related to 
alcohol or not. These are missed opportunities, which add-
up to lives lost. The UK-based NCEPOD report on alcohol-
related hospital admissions4 has highlighted a significant 
variability in practice with subsequent impact upon 
response to treatment and long-term survival. Long-term 
survival rates are good following an episode of Alcohol-
Related Liver Disease if the patient does not relapse back 
into harmful drinking. Complete abstinence from alcohol is 
usually necessary for optimum recovery. 
The process for 
compiling this Guidance
The Guidance was put together by a writing group 
comprised of health professionals specialising in 
liver care and/or public health. The group met on 
a regular basis and corresponded by email. 
Members of the writing group:
•  Professor John Dillon Consultant Hepatologist and 
Gastroenterologist, NHS Tayside, and Professor of 
Hepatology and Gastroenterology, University of Dundee
3  MacGilchrist, A (2013) Survey of liver services in Scotland http://ssg.rcpe.ac.uk/
sites/ssg/files/documents/survey%20of%20liver%20services%20in%20
Scotland.pdf
4  National Confidential Enquiry into Patient Outcome and Death (2013) Measuring 
the Units: A review of patients who died with alcohol-related liver disease 
www.ncepod.org.uk/2013report1/downloads/MeasuringTheUnits_
FullReport.pdf
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•	 	Dr	Alastair	MacGilchrist Consultant Hepatologist, NHS 
Lothian 
•  Dr Seonaid Anderson Consultant Psychiatrist, NHS 
Grampian
•	 	Karen	Matthews Hepatology Nurse Practitioner, NHS 
Lothian, and Professional Doctorate in Health Sciences, 
Queen Margaret University, Edinburgh
•  Dr Peter Rice Chair, Scottish Health Action on Alcohol 
Problems (SHAAP), and former Consultant Psychiatrist, 
NHS Tayside
•  Dr Eric Carlin Director, Scottish Health Action on 
Alcohol Problems (SHAAP)
•  Dr Lesley Graham Associate Specialist, Public Health, 
ISD, NSS and member of SHAAP steering group
•  Jennifer Fingland Policy Officer, Scottish Health Action 
on Alcohol Problems (SHAAP)
•  Dr Andrew Fraser Consultant Gastroenterologist, NHS 
Grampian
•  Dr Ewan Forrest Consultant Hepatologist and 
Gastroenterologist, NHS Greater Glasgow and Clyde
•	 	Dr	Mathis	Heydtmann	Consultant Hepatologist and 
Gastroenterologist, NHS Greater Glasgow and Clyde
•	 	Dr	Hasnain	Jafferbhoy	Consultant Gastroenterologist, 
NHS Fife
•  Dr Jacqueline Paterson Consultant Gastroenterologist, 
NHS Lothian
•  Dr Arun Chaudhuri Consultant Physician in Acute 
Medicine, NHS Tayside
To ensure the Guidance is representative of physician and 
patient needs, a consultation event was held in Edinburgh 
on 23rd June 2016. At the consultation event, the 
Guidance was discussed and participants were asked to 
vote on each recommendation using an electronic system. 
All of these recommendations were carefully re-considered 
while redrafting the Guidance. The consultation event 
was attended by a wide range of stakeholders including 
medical practitioners, third sector organisations, service 
users/patients and Scottish Government officials. A full list 
of invitees can be found in Appendix 3. 
The consultation event was followed by a period of follow-
up where attendees were given the opportunity to consider 
and offer further comment on the Guidance. The Medical 
Royal Colleges provided input through SHAAP. 
This Guidance has been timed to inform the Scottish 
Government’s ‘refresh’ of its national alcohol strategy and 
Ministers and civil servants have welcomed the process.
Evidence
The actions and recommendations contained within 
this document are based on evidence that: alcohol 
interventions reduce alcohol-related harm, alcohol 
causes liver damage, abstinence from alcohol 
prevents liver damage, and that alcohol-related liver 
disease disproportionately contributes to the mortality, 
morbidity and costs of alcohol-related harms. 
Firstly, the recommendations are based on the evidence for 
the impacts and benefits of interventions for the treatment of 
patients who consume hazardous levels of alcohol. There is 
clear evidence assessed by NICE5 that for non-dependent 
drinkers, brief interventions for alcohol are highly effective 
and cost-effective in reducing alcohol consumption and 
alcohol-related harm. In the case of dependent drinkers it 
is generally accepted that complex multi-partner agency 
interventions reduce alcohol consumption and alcohol-
related harm. This is government funded activity that has 
long been an established principle of the treatment and care 
pathway within the NHS and its third sector partners.
Secondly, that excess alcohol causes liver disease in 
susceptible individuals6. 
Thirdly, there is a large body of empirical evidence that, in 
those patients who present clinically with alcohol-related 
liver damage, abstinence or significant reduction in alcohol 
consumption dramatically improves prognosis, in terms of 
both survival and consumption of health care resources 
from further admissions to hospital7. Even in patients with 
cirrhosis, abstinence or significant reduction in alcohol 
consumption can lead to the liver reverting to a non-cirrhotic 
state, with a normal (synthetic) liver function. 
Fourthly, there is clear evidence that alcohol-related liver 
disease is a disease with high age-standardised mortality 
and morbidity with associated excessive health care costs 
and resource utilisation8. In England and Wales, 63% of all 
alcohol-related deaths in 2012 were caused by alcoholic 
liver disease. Liver disease is one of the few major causes 
of premature mortality that is increasing and deaths from 
liver disease have reached record levels, rising by 20% in a 
decade9. In Scotland, in 2007/8 there was a 400% increase 
5  Alcohol-use disorders: diagnosis, assessment and management of harmful 
drinking and alcohol dependence Clinical guideline. Published: 23 February 2011 
nice.org.uk/guidance/cg115
6  O’Shea RS, Srinivasan Dasarathy, McCullough AJ (2010) Alcoholic Liver Disease, 
American Journal Gastroenterology 2010; 105:14–32
7  Verrill C, Markham H, Templeton A, Carr NJ, Sheron N (2009) Alcohol-related 
cirrhosis-early abstinence is a key factor in prognosis, even in the most severe 
cases, Addiction; 104(5):768–774.
8  Corrao G, Bagnardi V, Zambon A, La VC (2004) A meta-analysis of alcohol 
consumption and the risk of 15 diseases, Prev Med; 38(5):613-619.
9  Academy of Medical Sciences (2004) Calling time: The nation’s drinking as a 
major health issue / BMA (2009) The human cost of alcohol misuse
in patients discharged from hospital with alcohol-related 
liver disease (6,817) compared to 199610. Treatment for 
alcohol-related conditions in Scotland costs over £1m a 
day. Further, it has been shown in modelling data that 
interventions to reduce alcohol consumption in these groups 
would be highly cost-effective.
Based on these lines of evidence we have drawn the 
conclusion that prioritising alcohol interventions to 
those with alcohol-related liver disease and developing 
approaches that assertively engage patients affected by 
alcohol-related liver disease would be a highly cost-effective 
and a lifesaving use of resources.
Aim of this Good 
Practice Guidance
The actions and recommendations contained 
within this document are based on evidence that: 
alcohol interventions reduce alcohol-related 
harm, alcohol causes liver damage, abstinence 
from alcohol prevents liver damage, and that 
alcohol-related liver disease disproportionately 
contributes to the mortality, morbidity and costs 
of alcohol-related harms.
The aim of this Guidance is to optimise the multi-
disciplinary care provided nationally to facilitate improved 
survival and optimum health in those affected by alcohol-
related liver disease. We present high-level actions for 
implementation across Scotland prioritising alcohol-
related liver disease for intervention by alcohol services 
and ensuring high-quality acute medical care for patients 
with alcohol-related liver disease across Scotland. To 
complement and underpin these we present a series of 
recommendations for an inclusive care pathway for all 
phases of alcohol-related liver disease.
Action 1
Specialist alcohol services should prioritise patients with 
evidence of alcohol-related liver damage for intervention. 
Services should actively, repeatedly and assertively 
engage with clients with alcohol-related liver damage.
Action 2
Patients admitted to hospital with alcohol-related liver 
failure should be managed immediately, in accordance 
with national guidelines, be reviewed by a physician with 
10  Scottish Government (2008) Costs of alcohol use and misuse in Scotland  
www.gov.scot/Resource/Doc/222103/0059736.pdf
expertise in liver disease and be engaged with an alcohol 
treatment service prior to discharge.
Action 3
Health boards and Integrated Joint Boards should facilitate 
the organisation of services to allow the operation of the 
care pathway recommendations.
Recommendations for 
an alcohol-related liver 
disease care pathway
Section 1: Identification and Early 
Assessment 
Background and rationale
Acute presentation of alcohol-related liver failure is 
dramatic and frequently fatal; however, this represents the 
“tip of the iceberg” and there is a large burden of treatable 
liver disease that is not identified and remains untreated. 
If identified and treated, progression to liver failure would, 
in many cases, be prevented. Interventions, both brief 
and more intensive, to decrease alcohol consumption 
are effective and reduce progression of liver disease. 
These are supported and described in NICE technology 
assessments111. This highlights the importance of early 
identification of vulnerable individuals for early intervention. 
Recommendations for GPs
1   In patients with abnormal LFTs or physical signs of 
liver damage the Fast Alcohol Screening Test (FAST) 
should be administered to all and they should be 
advised to abstain. 
2   All patients who have a FAST score of 3 or above 
should receive an Alcohol Brief Intervention (ABI) 
for alcohol misuse. Dependent drinkers, who can be 
defined as those with a FAST score >/=8 should be 
referred for further assessment and management by 
specialist alcohol services.
3   Men who report drinking over 50 units per week and 
women who report drinking over 35 units per week 
should have blood tests performed to assess their 
liver function, including liver enzymes, platelet count, 
synthetic liver function (albumin and prothrombin time) 
as well as a non-invasive liver fibrosis test12.
11  Alcohol-use disorders: diagnosis, assessment and management of harmful 
drinking and alcohol dependence Clinical guideline. Published: 23 February 
2011. nice.org.uk/guidance/cg115.
12 See Appendix 1 & 2.
SCOTTISH HEALTH ACTION ON ALCOHOL PROBLEMS  www.shaap.org.uk4
12 Queen Street, Edinburgh EH2 1JQ • Tel. 0131 247 3667 • Fax 0131 247 3664 • Email: shaap@rcpe.ac.uk
Alcohol-related Liver Disease: Guidance for Good Practice
4   Patients with abnormal liver biochemistry associated 
with excess alcohol consumption, which does not 
improve with three months of abstinence, or patients 
with elevated fibrosis scores should have a liver 
ultrasound scan and a full liver screen performed. 
5   Those patients above the threshold for fibrosis 
score, or with an abnormal ultrasound scan or with 
a positive liver screen for alternative liver diagnoses 
should be referred to local specialist liver services for 
assessment.
Recommendations for Alcohol / Addiction 
Services
This includes addictions services focussing on drug 
addiction as concomitant alcohol use can significantly 
worsen outcome.
6   Where alcohol has been identified as a contributing 
factor, all clients should be offered a test of liver 
fibrosis at presentation either on-site, by the patient’s 
GP or by another local service provider.
7   Patients above the threshold for fibrosis score, with 
an abnormal ultrasound scan or with a positive 
liver screen for alternative liver diagnoses should 
be referred to local specialist liver services for 
assessment. The referral should be made by the 
alcohol service, or they should ensure that another 
practitioner has done so.
8   Patients with abnormal fibrosis scores should be 
prioritised for treatment, for treatment intensification 
and for re-engagement with alcohol services if they 
default from follow-up and have on-going problems. 
9   Patients with on-going alcohol use who are still 
in contact with alcohol services should have 
reassessment of liver fibrosis undertaken annually.
10  All staff involved in patient care should have training 
to increase awareness of symptoms and signs of 
alcohol-related liver disease.
Recommendations for Acute General Hospital
This includes all admissions to all hospital departments.
11   All adult patients, irrespective of the reason for 
assessment and/or admission to hospital, should 
have a FAST test administered upon admission. The 
FAST questionnaire should also be included in the 
assessment documentation for every adult patient 
admitted to hospital. Alcohol should be considered as 
a factor in paediatric admissions.
12  Men who report drinking over 50 units per week and 
women who report drinking over 35 units per week 
should have blood tests performed to assess their 
liver function, including liver enzymes, platelet count, 
synthetic liver function (albumin and prothrombin time) 
as well as a non-invasive liver fibrosis test13.
13  All patients who have a FAST score of 3 or above 
should receive a test of liver fibrosis and an Alcohol 
Brief Intervention (ABI) for alcohol misuse, even if they 
have another liver disease. This should be provided in 
hospital ideally by an alcohol liaison team, but at least 
by staff able to refer on dependent drinkers to alcohol 
services.
14  All patients attending viral hepatitis services should 
have a FAST score and an ABI performed in those 
with a FAST score of 3 or above.
15  Alcohol should be considered as a possible co-factor 
for liver damage in all patients with abnormal liver 
enzymes. All patients attending out-patient services for 
an assessment of abnormal liver enzymes regardless 
of the aetiology should have a FAST score and an ABI 
considered in those with a FAST score of 3 or above. 
Recommendations in prisons, police custody, 
mental health services, sexual health services, 
and any other community settings where health 
questionnaires or assessments including ABIs 
are undertaken
16  All clients should be assessed for alcohol harms, by 
the FAST score.
17  All clients who have a FAST score of 3 or above 
should receive an Alcohol Brief Intervention (ABI) for 
alcohol misuse. 
18  All clients with a FAST score of 3 or above should be 
offered a test of liver fibrosis at the earliest opportunity 
(either on-site or by the patient’s GP).
19  Clients identified as having alcohol problems and an 
elevated test of liver fibrosis should be offered an 
ultrasound scan and be referred to specialist liver 
services.
20  All patients who have a FAST score of 3 or above 
should receive an Alcohol Brief Intervention (ABI) 
for alcohol misuse. Dependent drinkers, who can be 
defined as those with a FAST score >/=8 should be 
referred for further assessment and management by 
specialist alcohol services or to their GP depending on 
local referral protocols.
13 See Appendix 1.
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Section 2: Treatment of alcohol-related 
liver failure
Background and rationale
This section is focussed on the acute care of alcohol- 
related liver disease that has presented to clinical services 
with signs or symptoms of liver failure. The NCEPOD 2013 
report, “Measuring the Units”, highlighted improvements 
that could be made in the care of those requiring an acute 
hospital admission due to alcohol-related liver disease. 
This suggested that these could have resulted in reduced 
mortality and highlighted the standards required to provide 
good care and prevent avoidable deaths. Following on 
from this, the British Society of Gastroenterology and the 
British Association for the Study of the Liver have devised 
a care bundle incorporating best practices to be completed 
for all patients presenting with decompensated cirrhosis 
within six hours of acute admission into hospital. This will 
guide appropriate care prior to urgent liver specialist review 
within 24 hours.
Patients with alcohol-related liver disease are likely to 
have a range of other health needs, including their mental 
health, which should be managed appropriately.
Recommendations for General Practice/Hospital 
Receiving/Assessment Units
21  Patients presenting in general practice or acute 
admissions units with a history of alcohol problems 
and who are jaundiced or bleeding require urgent liver 
specialist assessment.
22  The initial urgent management of patients admitted to 
hospital should follow a locally adapted version of the 
BSG/BASL Cirrhosis Care Bundle. 
23  The use of the BSG/BASL Cirrhosis Care Bundle and 
its application to patients should be the subject of 
regular audit.
24  Patients admitted acutely with alcohol-related liver 
failure should be reviewed by a service with expertise 
in the management of liver disease within 24 hours of 
admission.
25  Patients admitted with alcohol-related liver failure 
must also be assessed in hospital prior to discharge 
by an alcohol care team, with planned follow-up. This 
should include an integrated care pathway utilising 
a multidisciplinary team including liver and addiction 
specialists. 
26  Decisions about the escalation of hospital level of care 
for patients with liver failure related to alcohol should 
be based on severity of the liver disease and the 
prognosis. Patients must not be denied higher-level 
care if clinically indicated. 
27  Hospital-based alcohol care services should be 
available seven days a week for those who need 
them, in line with BSG recommendations14.
Section 3: Follow-Up
Background and rationale
It is vital that individuals with alcohol-related liver disease 
coming into contact with clinical services or a multi-
disciplinary team have a plan for on-going follow-up and 
assessment. They remain a high mortality risk irrespective 
of whether the index contact with the healthcare system is 
through an acute hospital admission for decompensated 
alcohol-related liver disease or identification of chronic 
alcohol-related liver disease by another pathway. This 
process requires structuring of service provision by 
responsible health boards to enable cohesive integration 
of all services that contribute to care, including community 
and secondary care services. Furthermore, as described 
in the NICE 2015 quality standard, “Alcohol: preventing 
harmful alcohol use in the community”, this approach 
is fundamental to reducing harmful alcohol use in the 
community, preventing premature deaths and improving 
quality of life for those with long-term conditions.
Recommendations 
28  Health boards should ensure structures and 
clinical teams are in place to detect and deliver the 
interventions to reduce the impact of alcohol-related 
liver disease. These should be agreed with all 
professionals involved.
29  A follow-up plan for alcohol problems should be made 
for each patient assessed at or admitted to hospital 
with alcohol-related liver disease.
30  Any patient found to have alcohol-related liver disease 
with significant fibrosis, however detected, should be 
followed up by liver specialists and alcohol services or 
joint clinical services. 
31  Follow-up of patients with liver failure related to 
alcohol and/or alcohol-related liver disease should 
be holistic and based on an integrated care pathway 
utilising a multidisciplinary team including liver and 
addiction specialists. 
32  When appropriate, patients with alcohol-related liver 
failure should be assessed for liver transplantation as 
per NHSBT’s guidelines.
33  There should be a policy of assertively maintaining 
patients in treatment. Multiple strategies should be 
used to facilitate and maintain patient engagement 
with alcohol treatment services.
14  British Society of Gastroenterology (2011) Alcohol Care Teams  
www.bsg.org.uk/sections/liver-news/alcohol-care-teams.html
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Section 4: Recommendations for 
research
34  Research should be performed to evaluate (including 
health economics) the most effective means of 
assessing liver fibrosis in people at risk of alcohol-
related liver disease.
35  Research should be performed to discover the most 
effective way to engage with patients at risk of alcohol-
related liver failure as early as possible, so as to 
prevent harms. 
36  Research should be performed to evaluate models of 
access to alcohol treatment services and treatment 
options for those with alcohol-related liver failure, 
especially those who decline to attend services.
Appendix 1
Measures of liver fibrosis
The majority of people with alcohol problems will not have 
advanced alcohol-related liver disease. In the context of 
this Guidance it is intended to prioritise patients with liver 
damage for alcohol interventions to reduce consumption 
and to identify those patients who should be prioritised for 
alcohol interventions. To do this we recommend the use 
of tests of liver fibrosis which are based on markers of 
fibrosis and damage. Although they have been developed 
to try and detect cirrhosis of the liver, the aim of this 
Guidance is to prevent the development of cirrhosis, so 
we are focussed on those with developing liver damage 
and targeting them for alcohol interventions. We will use 
the lower thresholds of these fibrosis markers, which will 
enable us to identify those who might have liver damage 
and would be prioritised for alcohol intervention and  
follow-up. Within the group with raised fibrosis markers 
there will be a number who have advanced liver disease 
who will need further specialist assessment according to 
local arrangements that are already in place for patients 
with suspected chronic liver disease.
The assessment of liver fibrosis is complicated and is 
changing with technological advances. There are three 
types of technologies that allow the estimation of liver 
fibrosis: scores based on traditional blood tests, scores 
based on new biomarkers and imaging-based tests. 
Scores based on traditional liver blood tests are cheap 
and routinely available, they lack specificity for detection 
of cirrhosis and, in alcohol-related liver disease especially, 
may be over-sensitive, but in the context we intend their 
use in this Guidance, that is not a disadvantage. Scores 
based on new biomarkers are available from commercial 
sources, are more specific and are recommended by NICE 
for the detection of cirrhosis. These biomarkers are not 
routinely available anywhere in Scotland and their cost-
effectiveness in this context would need to be evaluated. 
Imaging-based testing such as Fibroscanning or liver 
stiffness measurement on abdominal ultrasound is the 
most expensive, and availability across Scotland is limited 
by capacity and again, the cost-effectiveness of using 
these techniques in this way requires assessment. It is 
important to note the emerging evidence that personalised 
biological information adds to the prevention impact of 
alcohol interventions and this may be different between the 
different techniques. 
The recommended preferred scores are based on the 
current evidence, availability of tests, and opportunity 
cost. The APRI score ((AST/Normal range of AST)/Platelet 
count X 100) and the FIB4 (FIB-4 = age (yr) x AST [U/L]/ 
(platelets [109/L] x (√ALT [U/L]), use routinely measured 
liver function tests. Some laboratories require a specific 
request for AST, but it is routinely available throughout 
Scotland and these are very cheap. These scores have 
been well validated in a wide variety of liver diseases. 
They may be less accurate in alcohol-related liver disease 
as alcohol may preferentially increase the AST. However, 
the result of this is to increase the sensitivity of the test so 
patients with advanced disease would still be referred for 
assessment. The recommended cut-offs for identification of 
patients at risk of fibrosis are APRI score greater than 0.7 
and FIB4 greater than 1.45.
Appendix 2
Definition of liver screen
The term ‘liver screen’ is used here to describe a group 
of blood tests that screen an individual with suspected 
chronic liver disease for a group of possible aetiologies for 
that disease. Alcohol-related liver disease would normally 
be diagnosed in the presence of liver damage, a history of 
excess alcohol and a negative liver screen.
The tests in a liver screen to investigate chronic liver 
disease include: viral serology for hepatitis B & C, tests for 
immunoglobulins and immunology for antibodies to smooth 
muscle, mitochondria and nuclear factor as well as liver 
kidney muscle (LKM) for auto-immune liver disease, ferritin 
for haemochromatosis, alpha 1antitryspin for its deficiency 
and caeruloplasmin to exclude Wilson’s disease in young 
patients. Metabolic syndrome (abnormal lipid profile, high 
blood pressure, obesity and / or diabetes mellitus / insulin 
resistance) should also be considered in all patients as part 
of the liver screen. An abdominal ultrasound is usually also 
performed as part of a liver screen.
7SCOTTISH HEALTH ACTION ON ALCOHOL PROBLEMS  www.shaap.org.uk
12 Queen Street, Edinburgh EH2 1JQ • Tel. 0131 247 3667 • Fax 0131 247 3664 • Email: shaap@rcpe.ac.uk
Alcohol-related Liver Disease: Guidance for Good Practice
Appendix 3
Invitees at consultation event, 23rd June 2016
Name Job title/role Organisation Contact 
Karen Addie Policy Manager Royal College of Psychiatrists 
in Scotland
Karen.Addie@rcpsych.ac.uk
Professor 
Mahmood Adil
Medical Director, Public 
Health and Intelligence
NHS National Services 
Scotland
mahmood.adil@nhs.net
Dr Seonaid 
Anderson
Consultant Psychiatrist NHS Grampian Seonaid.anderson@nhs.et
Dr Hilary Ansell Clinician National Coordinating Network 
for Healthcare and Forensic 
Medical Services for People in 
Police Care
Hilary.ansell@nhslothian.scot.nhs.uk
Colin Baptie Senior Charge Nurse, 
NHS Lothian
National Coordinating Network 
for Healthcare and Forensic 
Medical Services for People in 
Police Care
Colin.Baptie@nhslothian.scot.nhs.uk
Chanpreet Blayney Specialty Doctor NHS Lanarkshire chanpreet.blayney@nhs.net
Lynne Bower Specialist Alcohol 
Community Psychiatric 
Nurse
NHS Grampian lynnebower@nhs.net
 Adam Brodie Clinical Director Addiction Services, Lanarkshire a.brodie@nhs.net
Lynda Brown Public Health Adviser NHS Health Scotland Lynda.brown3@nhs.net
Elizabeth Butters Policy Officer West Lothian ADP Elizabeth.butters@westlothain.gov.uk
Tom Byrne National Prisons 
Pharmacy Adviser
Healthcare Improvement 
Scotland
thomasbyrne@nhs.net
David Cameron Senior Manager, 
Community Projects
Waverley Care David.Cameron@waverleycare.org
Dr Grace Campbell Clinician Healthcare Improvement 
Scotland
Grace.campbell@nhs.net
Dr Eric Carlin Director SHAAP SHAAP.Director@rcpe.ac.uk
Dr Catherine 
Chiang
Public Health NHS Greater Glasgow and 
Clyde
Catherine.Chiang@ggc.scot.nhs.uk
Graham Clark
Lynn Clark
Service user and 
partner
Sara Collier Standards and Policy 
Co-ordinator
Royal College of Physicians of 
Edinburgh
s.collier@rcpe.ac.uk
Hannah Cornish Programme Manager National Coordinating Network 
for Healthcare and Forensic 
Medical Services for People in 
Police Care
Hannah.cornish@nhs.net
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